Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
FASEB J ; 31(1): 47-59, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-27663861

RESUMEN

Membrane fusions that occur during vesicle transport, virus infection, and tissue development, involve receptors that mediate membrane contact and initiate fusion and effectors that execute membrane reorganization and fusion pore formation. Some of these fusogenic receptors/effectors are preferentially recruited to lipid raft membrane microdomains. Therefore, major constituents of lipid rafts, such as stomatin, may be involved in the regulation of cell-cell fusion. Stomatin produced in cells can be released to the extracellular environment, either through protein refolding to pass across lipid bilayer or through exosome trafficking. We report that cells expressing more stomatin or exposed to exogenous stomatin are more prone to undergoing cell fusion. During osteoclastogenesis, depletion of stomatin inhibited cell fusion but had little effect on tartrate-resistant acid phosphatase production. Moreover, in stomatin transgenic mice, increased cell fusion leading to enhanced bone resorption and subsequent osteoporosis were observed. With its unique molecular topology, stomatin forms molecular assembly within lipid rafts or on the appositional plasma membranes, and promotes membrane fusion by modulating fusogenic protein engagement.-Lee, J.-H., Hsieh, C.-F., Liu, H.-W., Chen, C.-Y., Wu, S.-C., Chen, T.-W., Hsu, C.-S., Liao, Y.-H., Yang, C.-Y., Shyu, J.-F., Fischer, W. B., Lin, C.-H. Lipid raft-associated stomatin enhances cell fusion.


Asunto(s)
Fusión Celular , Regulación de la Expresión Génica/fisiología , Microdominios de Membrana/fisiología , Proteínas de la Membrana/metabolismo , Animales , Células CHO , Cricetinae , Cricetulus , Células HEK293 , Humanos , Proteínas de la Membrana/genética , Ratones , Ratones Transgénicos , Osteoclastos/fisiología , Osteoporosis
2.
Cell Biol Int ; 40(8): 926-33, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27306251

RESUMEN

Placental trophoblast differentiation involves the continuous fusion of mononuclear cytotrophoblasts. However, except for syncytin, little is known about the detailed mechanisms underlying trophoblast fusion. A previous study indicated that lipid rafts play an important role in HTLV-1 syncytium formation. To identify proteins that may be involved in placental trophoblast differentiation, we examined stomatin, an important lipid-raft protein that localizes to detergent-resistant membrane domains. The syncytium and human chorionic gonadotropin (ß-hCG; a marker of placental trophoblast differentiation) were visualized by immunofluorescence staining. We found that overexpression of stomatin in the nonfusogenic JEG-3 cell line caused syncytium formation and increased the fusion index of cells. Treating these cells with N(6) ,2'-O-dibutyryladenosine 3',5'-cyclic monophosphate further increased cell fusion by stomatin. ß-hCG was found in a few JEG-3 cells overexpressing stomatin at 48 h, and its levels increased dramatically at 72 h along with the formation of the multinuclear syncytium. RNA interference was used to decrease stomatin expression in BeWo cells, a fusogenic human choriocarcinoma cell line. After knockdown for 72 h, stomatin levels decreased by almost 95%. The fusion indexes of control and stomatin-knockdown cells at 72 h were 9.4 and 6.5%, respectively. Our data indicated that stomatin could trigger syncytium formation and upregulate ß-hCG for cell fusion in nonfusogenic JEG-3 cells. Downregulation of stomatin slightly inhibited the fusion index of fusogenic BeWo cells. Thus, these data suggested that stomatin plays an important role in trophoblast differentiation.


Asunto(s)
Células Gigantes/metabolismo , Proteínas de la Membrana/biosíntesis , Placenta/citología , Bucladesina/farmacología , Diferenciación Celular/fisiología , Fusión Celular , Línea Celular Tumoral , Coriocarcinoma/metabolismo , Coriocarcinoma/patología , Gonadotropina Coriónica , Femenino , Productos del Gen env/metabolismo , Células Gigantes/citología , Células Gigantes/efectos de los fármacos , Humanos , Microdominios de Membrana/metabolismo , Proteínas de la Membrana/metabolismo , Placenta/efectos de los fármacos , Placenta/metabolismo , Embarazo , Proteínas Gestacionales/metabolismo , Interferencia de ARN , Trofoblastos/citología , Trofoblastos/efectos de los fármacos , Trofoblastos/metabolismo
3.
J Phys Ther Sci ; 26(9): 1509-13, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25276047

RESUMEN

[Purpose] Measurements of inspiratory strength are critical for detecting inspiratory muscle weakness. Sniff nasal inspiratory pressure (SNIP) is a quick, noninvasive measurement of global inspiratory strength; however, it is not clear how many trials are needed for reliable measurements. [Subjects and Methods] One hundred and nineteen subjects (age 39.9±16.5, range 18-69 yrs) completed the study. They were divided into subgroups of different ages and gender. Subjects were asked to take 20 maximal sniffs after normal expiration, with 30 seconds rest in-between. The highest values among the first 10 and last 10 SNIP maneuvers were recorded as SNIP1-10, and SNIP11-20, respectively. The paired t-test was used to compare the differences. Two-way measures ANOVA was used to compare the effects of age and gender on SNIP. [Results] SNIP 11-20 was significantly greater than SNIP1-10, suggesting that 10 trials is not enough to eliminate learning effects. Age did not affect SNIP in either gender, suggesting SNIP is preserved. In stepwise multiple linear regression analysis, the SNIP values were positively related with body mass index in women and positively related with weight in men. [Conclusion] The results suggest that twenty trials are needed for reliable SNIP measurements. The mean value and lower limits of normal SNIP are provided for clinical comparison.

4.
J Phys Ther Sci ; 26(9): 1503-8, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25276046

RESUMEN

[Purpose] To investigate the effects of Phase II cardiac exercise therapy (CET) on exercise capacity and changes in coronary risk factors (CRFs) of patients with acute myocardial infarction (AMI). [Subjects] Thirty male subjects with AMI were divided into an experimental group (EG) and a control group (CG). Another 30 age-matched subjects with patent coronary arteries served as a normal-control group (NCG). [Methods] Subjects in EG (n=20) trained using a stationary bicycle for 30 min at their target heart rate twice a week for 8 weeks. Exercise capacity was defined as the maximal metabolic equivalents (METs) that subjects reached during the symptom-limited maximal exercise test. HR, BP and RPP were recorded. Subjects in EG and CG received exercise tests and screening for CRFs at the beginning of, end of, and 3 months after Phase II CET, while subjects in NCG participated only in the 1st test. [Results] METs of CG did not improve until the 3rd test, while RPP at the 2nd test showed a significant increase. However, EG showed increased METs at the 2nd test without increase of RPP, and increased their high density lipoprotein cholesterol (HDL-C) during the follow-up period between the 2nd and 3rd tests. [Conclusion] Phase II CET shortens the recovery time of exercise capacity, helps to maintain the gained exercise capacity and increases HDL-C in phase III.

5.
Anticancer Drugs ; 24(10): 1047-57, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24025560

RESUMEN

BPR0C305 is a novel N-substituted indolyl glyoxylamide previously reported with in-vitro cytotoxic activity against a panel of human cancer cells including P-gp-expressing multiple drug-resistant cell sublines. The present study further examined the underlying molecular mechanism of anticancer action and evaluated the in-vivo antitumor activities of BPR0C305. BPR0C305 is a novel synthetic small indole derivative that demonstrates in-vitro activities against human cancer cell growth by inhibiting tubulin polymerization, disrupting cellular microtubule assembly, and causing cell cycle arrest at the G2/M phase. It is also orally active against leukemia and solid tumor growths in mouse models. Findings of these pharmacological and pharmacokinetic studies suggest that BPR0C305 is a promising lead compound for further preclinical developments.


Asunto(s)
Aminoquinolinas/farmacología , Antineoplásicos/farmacología , Indoles/farmacología , Microtúbulos/efectos de los fármacos , Administración Oral , Aminoquinolinas/administración & dosificación , Aminoquinolinas/farmacocinética , Aminoquinolinas/uso terapéutico , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/farmacocinética , Antineoplásicos/uso terapéutico , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Femenino , Humanos , Indoles/administración & dosificación , Indoles/farmacocinética , Indoles/uso terapéutico , Leucemia/tratamiento farmacológico , Leucemia/metabolismo , Leucemia/patología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos DBA , Ratones Desnudos , Microtúbulos/patología , Tubulina (Proteína)/metabolismo , Ensayos Antitumor por Modelo de Xenoinjerto
6.
Invest New Drugs ; 30(1): 164-75, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20890633

RESUMEN

Designed from a high throughput screened hit compound, novel 2-amino-1-thiazolyl imidazoles were synthesized and demonstrated cytotoxicity against human cancer cells. 1-(4-Phenylthiazol-2-yl)-4-(thiophen-2-yl)-1H-imidazol-2-amine (compound 2), a 2-amino-1-thiazolyl imidazole, inhibited tubulin polymerization, interacted with the colchicine-binding sites of tubulins, and caused cell cycle arrest at the G(2)/M phase in human gastric cancer cells. Disruption of the microtubule structure in cancer cells by compound 2 was also observed. Compound 2 concentration-dependently inhibited the proliferation of cancer cells in histocultured human gastric and colorectal tumors. Given orally, compound 2 prolonged the lifespans of leukemia mice intraperitoneally inoculated with the murine P388 leukemic cells. We report 2-amino-1-thiazolyl imidazoles as a novel class of orally active microtubule-destabilizing anticancer agents.


Asunto(s)
Antineoplásicos/administración & dosificación , Imidazoles/administración & dosificación , Neoplasias Experimentales/tratamiento farmacológico , Tiazoles/administración & dosificación , Moduladores de Tubulina/administración & dosificación , Administración Oral , Animales , Antineoplásicos/síntesis química , Antineoplásicos/metabolismo , Unión Competitiva , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Colchicina/metabolismo , Relación Dosis-Respuesta a Droga , Puntos de Control de la Fase G2 del Ciclo Celular/efectos de los fármacos , Humanos , Imidazoles/síntesis química , Imidazoles/metabolismo , Concentración 50 Inhibidora , Masculino , Ratones , Ratones Endogámicos DBA , Ratones Desnudos , Microtúbulos/efectos de los fármacos , Microtúbulos/metabolismo , Estructura Molecular , Neoplasias Experimentales/metabolismo , Neoplasias Experimentales/patología , Relación Estructura-Actividad , Tiazoles/síntesis química , Tiazoles/metabolismo , Factores de Tiempo , Tubulina (Proteína)/metabolismo , Moduladores de Tubulina/síntesis química , Moduladores de Tubulina/metabolismo
7.
Nat Commun ; 13(1): 4174, 2022 07 19.
Artículo en Inglés | MEDLINE | ID: mdl-35854007

RESUMEN

Regulation of fatty acid uptake, lipid production and storage, and metabolism of lipid droplets (LDs), is closely related to lipid homeostasis, adipocyte hypertrophy and obesity. We report here that stomatin, a major constituent of lipid raft, participates in adipogenesis and adipocyte maturation by modulating related signaling pathways. In adipocyte-like cells, increased stomatin promotes LD growth or enlargements by facilitating LD-LD fusion. It also promotes fatty acid uptake from extracellular environment by recruiting effector molecules, such as FAT/CD36 translocase, to lipid rafts to promote internalization of fatty acids. Stomatin transgenic mice fed with high-fat diet exhibit obesity, insulin resistance and hepatic impairments; however, such phenotypes are not seen in transgenic animals fed with regular diet. Inhibitions of stomatin by gene knockdown or OB-1 inhibit adipogenic differentiation and LD growth through downregulation of PPARγ pathway. Effects of stomatin on PPARγ involves ERK signaling; however, an alternate pathway may also exist.


Asunto(s)
Adipogénesis , Gotas Lipídicas , Adipogénesis/genética , Animales , Antígenos CD36/genética , Antígenos CD36/metabolismo , Dieta Alta en Grasa , Ácidos Grasos/metabolismo , Gotas Lipídicas/metabolismo , Metabolismo de los Lípidos , Sistema de Señalización de MAP Quinasas , Ratones , Obesidad/genética , Obesidad/metabolismo , PPAR gamma/genética , PPAR gamma/metabolismo
8.
Cancer Sci ; 102(1): 182-91, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21040217

RESUMEN

BPR0C261 is a synthetic small molecule compound cytotoxic against human cancer cells and active prolonging the lifespan of leukemia mice. In the present study, we further investigated the mechanisms of its anticancer action and found that BPR0C261 inhibited microtubule polymerization through interacting with the colchicine binding sites on tubulins, disrupted microtubule arrangement and caused cell cycle arrest at G(2)/M phase in cancer cells. BPR0C261 also inhibited the clonogenic growths of cancer cells and showed cytotoxicity against human cervical cancer cells of multidrug-resistant phenotype. In addition, BPR0C261 concentration-dependently inhibited the proliferation and migration of HUVECs and disrupted the endothelial capillary-like tube formations in HUVEC and rat aorta ring cultures. Given orally, BPR0C261 inhibited angiogenesis in s.c. implanted Matrigel plugs in mice. Notably, its IC(50) values against the endothelial cell growths were approximately 10-fold lower than those against the cancer cells. It was found orally absorbable in mice and showed a good oral bioavailability (43%) in dogs. BPR0C261 permeated through the human intestinal Caco-2 cell monolayer, suggesting oral availability in humans. Orally absorbed BPR0C261 distributed readily into the s.c. xenografted tumors in nude mice in which the tumor tissue levels of BPR0C261 were found oral dose-dependent. BPR0C261 showed in vivo activities against human colorectal, gastric, and nasopharyngeal tumors in nude mice. Most interestingly, the combination of BPR0C261 plus cisplatin synergistically prolonged the lifespans of mice inoculated with murine leukemia cells. Thus, BPR0C261 is a novel orally active tubulin-binding antitumor agent with antimitotic, apoptosis-inducing, and vasculature disrupting activities.


Asunto(s)
Inhibidores de la Angiogénesis/farmacología , Antimitóticos/farmacología , Antineoplásicos/farmacología , Indoles/farmacología , Tiazoles/farmacología , Administración Oral , Animales , Antineoplásicos/farmacocinética , Apoptosis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Perros , Humanos , Leucemia Experimental/tratamiento farmacológico , Masculino , Ratones , Ratones Endogámicos , Microtúbulos/química , Microtúbulos/efectos de los fármacos , Ratas , Ratas Sprague-Dawley
9.
J Med Chem ; 46(9): 1706-15, 2003 Apr 24.
Artículo en Inglés | MEDLINE | ID: mdl-12699388

RESUMEN

A series of N-heterocyclic indolyl glyoxylamides were synthesized and evaluated for in vitro and in vivo anticancer activities. They exhibited a broad spectrum of anticancer activity not only in murine leukemic cancer cells but also in human gastric, breast, and uterus cancer cells as well as their multidrug resistant sublines with a wide range of IC(50) values. They also induced apoptosis and caused DNA fragmentation in human gastric cancer cells. Among the compounds studied, 7 showed the most potent activity of growth inhibition (IC(50) = 17-1711 nM) in several human cancer cells. Given orally, compounds 7 and 13 dose-dependently prolonged the survival of animals inoculated with P388 leukemic cancer cells. N-Heterocyclic indolyl glyoxylamides may be useful as orally active chemotherapeutic agents against cancer and refractory cancerous diseases of multidrug resistance phenotype.


Asunto(s)
Antineoplásicos/síntesis química , Glioxilatos/síntesis química , Indoles/síntesis química , Tiazoles/síntesis química , Administración Oral , Animales , Antineoplásicos/química , Antineoplásicos/farmacología , Apoptosis , División Celular/efectos de los fármacos , Resistencia a Múltiples Medicamentos , Resistencia a Antineoplásicos , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Glioxilatos/química , Glioxilatos/farmacología , Humanos , Indoles/química , Indoles/farmacología , Leucemia P388/mortalidad , Ratones , Ratones Endogámicos DBA , Trasplante de Neoplasias , Relación Estructura-Actividad , Tiazoles/química , Tiazoles/farmacología , Células Tumorales Cultivadas
10.
Biochem Pharmacol ; 79(9): 1261-71, 2010 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-20034474

RESUMEN

Microtubule is a popular target for anticancer drugs. Chamaecypanone C, is a natural occurring novel skeleton compound isolated from the heartwood of Chamaecyparis obtusa var. formosana. The present study demonstrates that chamaecypanone C induced mitotic arrest through binding to the colchicine-binding site of tubulin, thus preventing tubulin polymerization. In addition, cytotoxic activity of chamaecypanone C in a variety of human tumor cell lines has been ascertained, with IC(50) values in nanomolar ranges. Flow cytometric analysis revealed that chamaecypanone C treated human KB cancer cells were arrested in G(2)-M phases in a time-dependent manner before cell death occurred. Additional studies indicated that the effect of Chamaecypanone C on cell cycle arrest was associated with an increase in cyclin B1 levels and a mobility shift of Cdc2/Cdc25C. The changes in Cdc2 and Cdc25C coincided with the appearance of phosphoepitopes recognized by a marker of mitosis, MPM-2. Interestingly, this compound induced apoptotic cell death through caspase 8-Fas/FasL dependent pathway, instead of mitochondria/caspase 9-dependent pathway. Notably, several KB-derived multidrug resistant cancer cell lines overexpressing P-gp170/MDR and MRP were sensitive to Chamaecypanone C. Taken together, these findings indicated that Chamaecypanone C is a promising anticancer compound that has potential for management of various malignancies, particularly for patients with drug resistance.


Asunto(s)
Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Compuestos Bicíclicos con Puentes/farmacología , Caspasa 8/metabolismo , Proteína Ligando Fas/metabolismo , Microtúbulos/efectos de los fármacos , Receptor fas/metabolismo , Caspasa 8/genética , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Resistencia a Antineoplásicos , Proteína Ligando Fas/genética , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Estructura Molecular , Receptor fas/genética
11.
J Med Chem ; 53(6): 2409-17, 2010 Mar 25.
Artículo en Inglés | MEDLINE | ID: mdl-20170097

RESUMEN

2-Amino-1-arylidenaminoimidazoles, a novel class of orally (po) active microtubule-destabilizing anticancer agents, were synthesized. The compounds were designed from a hit compound identified in a drug discovery platform by using cancer cell-based high throughput screening assay. Selective synthesized compounds exerted cell cytotoxicity against human cancer cells. The underlying mechanisms for the anticancer activity were demonstrated as interacting with the tubulins and inhibiting microtubule assembly, leading to proliferation inhibition and apoptosis induction in the human tumor cells. Furthermore, two compounds showed in vivo anticancer activities in both po and intravenously (iv) administered routes and prolonged the life spans of murine leukemic P388 cells-inoculated mice. These new po active antimitotic anticancer agents are to be further examined in preclinical studies and developed for clinical uses.


Asunto(s)
Antineoplásicos/farmacología , Imidazoles/síntesis química , Imidazoles/farmacología , Neoplasias/tratamiento farmacológico , Administración Oral , Animales , Antineoplásicos/administración & dosificación , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Fragmentación del ADN/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Imidazoles/química , Concentración 50 Inhibidora , Leucemia P388/tratamiento farmacológico , Leucemia P388/patología , Ratones , Ratones Endogámicos DBA , Ratones Desnudos , Microtúbulos/efectos de los fármacos , Microtúbulos/metabolismo , Modelos Químicos , Estructura Molecular , Neoplasias/patología , Relación Estructura-Actividad , Tubulina (Proteína)/metabolismo , Ensayos Antitumor por Modelo de Xenoinjerto
12.
J Biol Chem ; 284(6): 3855-64, 2009 Feb 06.
Artículo en Inglés | MEDLINE | ID: mdl-18996841

RESUMEN

The cyclic calcium release and uptake during calcium oscillation are thought to result from calcium-induced calcium release (CICR); however, it is unclear, especially in nonexcitable cells, how the initial calcium mobilization that triggers CICR occurs. We report here a novel mechanism, other than conventional calcium channels or the phopholipase C-inositol trisphosphate system, for initiating calcium oscillation downstream of integrin signaling. Upon integrin alphaIIbbeta3 binding to fibrinogen ligand or the disintegrin rhodostomin, sodium-proton exchanger NHE1 and sodium-calcium exchanger NCX1 are actively transported to the plasma membrane, and they become physically coupled to integrin alphaIIbbeta3. Lipid raft-dependent mechanisms modulate the membrane targeting and formation of the NHE1-integrin alphaIIbbeta3-NCX1 protein complex. NHE1 and NCX1 within such protein complex are functionally coupled, such that a local increase of sodium concentration caused by NHE1 can drive NCX1 to generate sodium efflux in exchange for calcium influx. The resulting calcium increase inside the cell can then trigger CICR as a prelude to calcium oscillation downstream of integrin alphaIIbbeta3 signaling. Fluorescence resonance energy transfer based on fluorescence lifetime measurements is employed here to monitor the intermolecular interactions among NHE1-integrin alphaIIbbeta3-NCX1, which could not be properly detected using conventional biochemical assays.


Asunto(s)
Señalización del Calcio/fisiología , Calcio/metabolismo , Proteínas de Transporte de Catión/metabolismo , Microdominios de Membrana/metabolismo , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/metabolismo , Intercambiador de Sodio-Calcio/metabolismo , Intercambiadores de Sodio-Hidrógeno/metabolismo , Animales , Relojes Biológicos/fisiología , Células CHO , Proteínas de Transporte de Catión/genética , Cricetinae , Cricetulus , Fibrinógeno/genética , Fibrinógeno/metabolismo , Humanos , Inositol 1,4,5-Trifosfato , Microdominios de Membrana/genética , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/genética , Transporte de Proteínas/fisiología , Sodio/metabolismo , Intercambiador de Sodio-Calcio/genética , Intercambiador 1 de Sodio-Hidrógeno , Intercambiadores de Sodio-Hidrógeno/genética , Fosfolipasas de Tipo C/genética , Fosfolipasas de Tipo C/metabolismo
13.
Bioorg Med Chem Lett ; 15(13): 3271-5, 2005 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-15927466

RESUMEN

To find potent and selective inhibitors of dipeptidyl peptidase IV (DPP-IV), we synthesized a series of 2-cyanopyrrolidine with P2-site 4-substituted glutamic acid derivatives and tested their activities against DPP-IV, DPP8, and DPP-II. Analogues that incorporated a bulky substituent at the first carbon position of benzylamine or isoquinoline showed over 30-fold selectivity for DPP-IV over both DPP8 and DPP-II. From structure-activity relationship studies, we speculate that the S2 site of DPP8 might be similar to that of DPP-IV, while DPP-IV inhibitor with N-substituted glycine in the P2 site and/or with a moiety involving in hydrophobic interaction with the side chain of Phe357 might provide a better selectivity for DPP-IV over DPP8.


Asunto(s)
Dipeptidil-Peptidasas y Tripeptidil-Peptidasas/antagonistas & inhibidores , Inhibidores Enzimáticos/síntesis química , Ácido Glutámico/análogos & derivados , Inhibidores de la Adenosina Desaminasa , Sitios de Unión , Dipeptidasas/antagonistas & inhibidores , Dipeptidil Peptidasa 4 , Inhibidores Enzimáticos/farmacología , Ácido Glutámico/síntesis química , Ácido Glutámico/farmacología , Glicoproteínas/antagonistas & inhibidores , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Concentración 50 Inhibidora , Modelos Moleculares , Unión Proteica , Pirrolidinas/síntesis química , Pirrolidinas/farmacología , Relación Estructura-Actividad
14.
J Biomed Sci ; 11(5): 631-40, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15316139

RESUMEN

Breakdown of the cytoskeletal network and redistribution of cytoplasmic organelles are early events of programmed cell death. Previous studies showed that retinoic acid induces programmed cell death in many tumor cell lines and that cytokeratins, particularly cytokeratin 18, are affected in the early events of apoptosis. In this study, patterns of cytoplasmic intermediate filaments (cytokeratin 18), actin filaments, and microtubules, as well as Bax and Bcl-2 proteins in human bladder carcinoma T24 cells were examined before and after retinoic acid treatment by immunocytochemistry and conventional electron microscopy. Our results demonstrate that the redistribution of Bax and Bcl-2 proteins in the subcellular compartment of T24 cells is correlated with reorganization of the cytoplasmic intermediate filament network and that cytokeratins are cleaved by caspases, as revealed by the M30 antibody which recognizes a specific caspase cleavage site within cytokeratin 18. The cytoskeletal architectures of microtubules are not significantly affected in the early apoptotic process, from our observations. We suggest that the breakdown in the intermediate filament network associated with the aggregation of mitochondria and lysosome may be a crucial event in the apoptotic process and that aggregation of cytoplasmic Bax may accelerate apoptotic death.


Asunto(s)
Apoptosis/efectos de los fármacos , Retinoides/farmacología , Neoplasias de la Vejiga Urinaria/patología , Línea Celular Tumoral , Humanos , Queratinas/análisis , Neoplasias de la Vejiga Urinaria/ultraestructura
15.
Bioorg Med Chem Lett ; 13(1): 101-5, 2003 Jan 06.
Artículo en Inglés | MEDLINE | ID: mdl-12467626

RESUMEN

Compounds 1-5, structurally related to combretastatin A-4 showed excellent cytotoxic activities against a panel of human cancer cell lines including multi-drug resistant cell lines. The X-ray three-dimensional structural analysis shows that proton donor in B ring may be required for cytotoxic activity, with intermolecular hydrogen bonding playing an important role.


Asunto(s)
Antineoplásicos/química , Benzofenonas/síntesis química , Estilbenos , Antineoplásicos/farmacología , Benzofenonas/farmacología , Bibencilos/química , Ciclo Celular/efectos de los fármacos , Cristalografía por Rayos X , Resistencia a Múltiples Medicamentos , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Concentración 50 Inhibidora , Modelos Moleculares , Estructura Molecular , Relación Estructura-Actividad , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda